Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody
Description
Definition and Mechanism
The antibody targets the phosphorylated form of EGFR at Y1068, a key residue in the kinase domain that mediates receptor dimerization and signal transduction . Phosphorylation at Y1068 activates pathways such as RAS-RAF-MEK-ERK and PI3K-AKT, which are implicated in oncogenesis and targeted therapy resistance . The recombinant monoclonal format ensures consistent production via genetic engineering, avoiding reliance on animal-derived sources .
Primary Applications
Validation Methods
-
Peptide Inhibition Assay: Pre-treatment with phospho-specific peptide abolishes WB signal, confirming specificity .
-
EGF Stimulation: A431 cells treated with 50–100 ng/mL EGF show time-dependent phosphorylation (5–30 minutes) .
-
Cross-Reactivity Testing: Reactivity with mouse/rat EGFR confirmed in select antibodies .
EGFR Signaling Dynamics
-
EGF-Induced Phosphorylation: EGF stimulation (100 ng/mL, 5–30 minutes) robustly induces Y1068 phosphorylation in A431 cells, detectable via WB and FC .
-
Pathway Activation: Meprinα protease enhances EGFR-Y1068 phosphorylation, promoting ERK1/2 activation and cell migration .
-
Glycosylation Impact: Observed band sizes (175–190 kDa) exceed predicted MW due to glycosylation and other post-translational modifications .
Clinical Relevance
-
Cancer Research: EGFR-Y1068 phosphorylation is linked to oncogenesis and resistance to EGFR inhibitors (e.g., gefitinib) .
-
Diagnostic Utility: IHC detection of phospho-EGFR-Y1068 in cervical cancer tissues highlights its potential in biomarker studies .
Optimal Usage Guidelines
Product Specs
The phospho-EGFR (Y1068) recombinant monoclonal antibody is produced through the utilization of protein technology and DNA recombinant techniques. Initially, animals are immunized with a synthesized peptide derived from human phospho-EGFR (Y1068). Subsequently, B cells are extracted from the immunized animals. Through a rigorous screening process, positive B cells are selected and undergo single clone identification. The light and heavy chains of the phospho-EGFR (Y1068) antibody are then amplified using PCR and inserted into a plasmid vector, resulting in a recombinant vector. This recombinant vector is then transfected into host cells for the expression of the antibody. Finally, the phospho-EGFR (Y1068) recombinant monoclonal antibody is purified from the cell culture supernatant using affinity chromatography. This antibody is recommended for use in ELISA and WB for the detection of human EGFR phosphorylated at the Y1068 residue.
Target Background
Epidermal growth factor receptor (EGFR) serves as a receptor for ligands belonging to the EGF family, triggering the activation of multiple signaling cascades. These cascades effectively translate extracellular cues into appropriate cellular responses. Notable ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG, and HBEGF/heparin-binding EGF. Ligand binding induces receptor homo- and/or heterodimerization, leading to autophosphorylation on critical cytoplasmic residues. This phosphorylation event facilitates the recruitment of adapter proteins like GRB2, which in turn activates intricate downstream signaling cascades.
EGFR activates at least four major downstream signaling cascades, encompassing the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs modules. It may also activate the NF-kappa-B signaling cascade. Notably, EGFR directly phosphorylates other proteins like RGS16, stimulating its GTPase activity and potentially coupling EGF receptor signaling to G protein-coupled receptor signaling. EGFR also phosphorylates MUC1, enhancing its interaction with SRC and CTNNB1/beta-catenin.
EGFR positively regulates cell migration through its interaction with CCDC88A/GIV. This interaction retains EGFR at the cell membrane following ligand stimulation, thereby promoting EGFR signaling and triggering cell migration. EGFR plays a crucial role in enhancing learning and memory performance. Isoform 2 of EGFR may act as an antagonist of EGF action. In the context of microbial infection, EGFR acts as a receptor for hepatitis C virus (HCV) in hepatocytes, facilitating its entry into cells. EGFR mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes essential for HCV entry and enhancing membrane fusion of cells expressing HCV envelope glycoproteins.
- Amphiregulin, contained in non-small-cell lung carcinoma-derived exosomes, induces osteoclast differentiation through the activation of the EGFR pathway. PMID: 28600504
- Combining vorinostat with an EGFRTKI can reverse EGFRTKI resistance in NSCLC. PMID: 30365122
- The feasibility of using the radiocobalt labeled antiEGFR affibody conjugate ZEGFR:2377 as an imaging agent has been investigated. PMID: 30320363
- Among all transfection complexes, 454 lipopolyplexes modified with the bidentate PEG-GE11 agent demonstrate the best EGFR-dependent uptake, as well as luciferase and NIS gene expression into cells. PMID: 28877405
- EGFR amplification was observed to be higher in the OSCC group compared to the control group (P=0.018) and was associated with advanced clinical stage (P=0.013), independent of age. Patients with EGFR overexpression exhibited worse survival rates, as did patients with T3-T4 tumors and positive margins. EGFR overexpression has a negative impact on disease progression. PMID: 29395668
- Clonal analysis reveals that the dominant JAK2 V617F-positive clone in Polycythemia Vera harbors EGFR C329R substitution, suggesting that this mutation might contribute to clonal expansion. PMID: 28550306
- Baseline circulating tumor cell count could be a predictive biomarker for EGFR-mutated and ALK-rearranged non-small cell lung cancer, offering better guidance and monitoring for patients undergoing molecular targeted therapies. PMID: 29582563
- High EGFR expression is linked to cystic fibrosis. PMID: 29351448
- Research suggests a mechanism for EGFR inhibition to suppress respiratory syncytial virus by activating endogenous epithelial antiviral defenses. PMID: 29411775
- This study identified the emergence of the T790M mutation within the EGFR cDNA in a subset of erlotinib-resistant PC9 cell models using Sanger sequencing and droplet digital PCR-based methods, demonstrating that the T790M mutation can arise through de novo events following treatment with erlotinib. PMID: 29909007
- The present study demonstrated that miR145 regulates the EGFR/PI3K/AKT signaling pathway in patients with nonsmall cell lung cancer. PMID: 30226581
- Among NSCLC patients treated with EGFR-TKI, those with T790M mutations were found to frequently also show 19 dels, compared to T790M-negative patients. Additionally, T790M-positive patients exhibited a longer PFS. Consequently, screening these patients for T790M mutations may contribute to improved survival. PMID: 30150444
- High EGFR expression is associated with Breast Carcinoma. PMID: 30139236
- Results indicate that CAV-1 promotes anchorage-independent growth and anoikis resistance in detached SGC-7901 cells. This effect is linked to the activation of Src-dependent epidermal growth factor receptor-integrin beta signaling, as well as the phosphorylation of PI3K/Akt and MEK/ERK signaling pathways. PMID: 30088837
- Findings suggest that FOXK2 inhibits the malignant phenotype of clear-cell renal cell carcinoma and acts as a tumor suppressor, potentially through the inhibition of EGFR. PMID: 29368368
- The EGFR mutation status in advanced non-small cell lung cancer (NSCLC) patients has undergone significant alterations. PMID: 30454543
- Different signaling pathways play a role in regulating PD-L1 expression in EGFR-mutated lung adenocarcinoma. PMID: 30454551
- Internal tandem duplication of the kinase domain delineates a genetic subgroup of congenital mesoblastic nephroma that transcends histological subtypes. PMID: 29915264
- The expression level of EGFR increased with higher stages and pathological grades of BTCC. Notably, the significantly increased expression of HER-2 was statistically associated with clinical stages and tumor recurrence. Furthermore, the expression level of HER-2 increased with higher clinical stages of BTCC. EGFR expression and HER-2 levels exhibited a positive correlation in BTCC samples. PMID: 30296252
- Results indicate that GGA2 interacts with the EGFR cytoplasmic domain to stabilize its expression and reduce its lysosomal degradation. PMID: 29358589
- Combination therapy of apatinib with icotinib for primary acquired resistance to icotinib might be a viable option for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. However, clinicians must also be aware of the potential side effects associated with such therapy. PMID: 29575765
- This report presents a rare case manifesting as multiple lung adenocarcinomas with four distinct EGFR gene mutations identified in three lung tumors. PMID: 29577613
- Research supports the involvement of EGFR, HER2, and HER3 in BCC aggressiveness and in tumor differentiation towards distinct histological subtypes. PMID: 30173251
- The ratio of sFlt-1/sEGFR could serve as a novel candidate biochemical marker for monitoring the severity of preterm preeclampsia. sEndoglin and sEGFR might be involved in the pathogenesis of small for gestational age in preterm preelampsia. PMID: 30177039
- This study confirms the prognostic effect of EGFR and VEGFR2 for recurrent disease and survival rates in patients with epithelial ovarian cancer. PMID: 30066848
- Data suggest that diagnostic or therapeutic chest radiation might predispose patients with decreased stromal PTEN expression to secondary breast cancer, and that prophylactic EGFR inhibition could potentially reduce this risk. PMID: 30018330
- Research suggests a unique regulatory feature of PHLDA1, which inhibits the ErbB receptor oligomerization process and thereby controls the activity of the receptor signaling network. PMID: 29233889
- This study observed not only EGFR C797S mutation but also L792F/Y/H in three NSCLC clinical subjects exhibiting acquired resistance to osimertinib treatment. PMID: 28093244
- Data reveal that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was considerably higher than that of non-invasive GHPA. PMID: 29951953
- Concurrent mutations in genes such as CDKN2B or RB1 were associated with a worse clinical outcome in lung adenocarcinoma patients with EGFR active mutations. PMID: 29343775
- The ER-alpha36/EGFR signaling loop promotes the growth of hepatocellular carcinoma cells. PMID: 29481815
- High EGFR expression is associated with colorectal cancer. PMID: 30106444
- High EGFR expression is linked to gefitinib resistance in lung cancer. PMID: 30106446
- High EGFR expression is associated with tumor-node-metastasis in nonsmall cell lung cancer. PMID: 30106450
- Data suggest that Thr264 in TRPV3 is a key ERK1 phosphorylation site that mediates EGFR-induced sensitization of TRPV3 to stimulate signaling pathways involved in regulating skin homeostasis. (TRPV3 = transient receptor potential cation channel subfamily V member-3; ERK1 = extracellular signal-regulated kinase-1; EGFR = epidermal growth factor receptor) PMID: 29084846
- The EGFR mutation frequency in Middle East and African patients is higher than that observed in white populations but still lower than the frequency reported in Asian populations. PMID: 30217176
- EGFR-containing exosomes derived from cancer cells could favor the development of a liver-like microenvironment, promoting liver-specific metastasis. PMID: 28393839
- Results indicate that the EGF-STAT3 signaling pathway promotes and maintains colorectal cancer (CRC) stemness. Additionally, a crosstalk between STAT3 and Wnt activates the Wnt/beta-catenin signaling pathway, which also contributes to cancer stemness. Thus, STAT3 emerges as a potential therapeutic target for CRC treatment. PMID: 30068339
- This study revealed that the T790M mutation is not only associated with EGFR-TKI resistance but may also play a functional role in the malignant progression of lung adenocarcinoma. PMID: 29887244
- LOX regulates EGFR cell surface retention to drive tumor progression. PMID: 28416796
- In a Han Chinese population, EGFR gene polymorphisms, rs730437 and rs1468727, and haplotype A-C-C were found to be potential protective factors against the development of Alzheimer's Disease. PMID: 30026459
- EGFR proteins at different cellular locations in lung adenocarcinoma might influence the biology of cancer cells and serve as an independent indicator of a more favorable prognosis and treatment response. PMID: 29950164
- This report presents the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, a novel EGFR TKI that binds to EGFR reversibly and does not rely on Cys 797. PMID: 29802850
- Overexpression of miR-452-3p promoted cell proliferation and mobility while suppressing apoptosis. MiR-452-3p enhanced EGFR and phosphorylated AKT (pAKT) expression, but inhibited p21 expression levels. MiR-452-3p promoted hepatocellular carcinoma (HCC) cell proliferation and mobility by directly targeting the CPEB3/EGFR axis. PMID: 29332449
- This study reveals that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
- BRAF and EGFR inhibitors demonstrate synergistic effects in increasing cytotoxic effects and decreasing stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. PMID: 29534162
- This study confirms a direct correlation between MSI1 and EGFR, potentially supporting the significant role of MSI1 in activating EGFR through NOTCH/WNT pathways in esophageal squamous cell carcinoma. PMID: 30202417
- Three lines of tyrosine kinase inhibitors (TKIs) therapy can prolong survival in non-small cell lung cancer (NSCLC) patients. Elderly patients can benefit from TKI therapy. EGFR mutation-positive patients can benefit from second-line or third-line TKI therapy. PMID: 29266865
- EGFR 19Del and L858R mutations serve as valuable biomarkers for predicting the clinical response to EGFR-TKIs. 19Del mutations may be associated with a better clinical outcome. PMID: 29222872
- HMGA2-EGFR constitutively induced a higher level of phosphorylated STAT5B compared to EGFRvIII. PMID: 29193056
Q&A
What is the significance of EGFR Y1068 phosphorylation in cellular signaling?
EGFR phosphorylation at Y1068 serves as a critical binding site for signaling adaptors, particularly the Grb2:Cbl complex. This phosphorylation site is not only necessary but also sufficient for EGFR ubiquitination, along with Y1045 and Y1086. These phosphorylation events trigger downstream signaling cascades that regulate cell proliferation, survival, and differentiation. The phosphorylation status at Y1068 is therefore a key indicator of EGFR activation and function in both normal and pathological contexts .
How can I validate the specificity of Phospho-EGFR (Y1068) antibodies?
To validate specificity, researchers should use appropriate positive and negative controls. A commonly employed method is comparing A431 human epithelial carcinoma cells with and without EGF treatment. Western blot analysis should show detection of a specific band at approximately 190 kDa in EGF-treated samples, with minimal to no detection in untreated samples. Additionally, using EGFR kinase inhibitors like C56 can confirm specificity, as they should abrogate the signal in stimulated cells .
What are the recommended applications for Phospho-EGFR (Y1068) antibodies?
Phospho-EGFR (Y1068) antibodies have been validated for multiple applications including Western blotting, flow cytometry, and CyTOF (mass cytometry). For Western blotting, these antibodies typically work well under reducing conditions, with PVDF membranes and appropriate buffer systems. For flow cytometry, cells must be fixed with paraformaldehyde and permeabilized (often with saponin) to facilitate intracellular staining .
What is the relationship between EGFR mutation status and Y1068 phosphorylation in predicting response to EGFR-TKIs?
While EGFR mutations are strong predictors of response to EGFR tyrosine kinase inhibitors (TKIs), approximately 10% of patients with wild-type EGFR also respond to these therapies. Research has shown that pTyr1068 expression may serve as an independent predictive biomarker for TKI response. In a study of 205 non-small cell lung cancer patients, those with pTyr1068 expression demonstrated superior progression-free survival after EGFR-TKI therapy compared to those without expression (median PFS 7.0 months vs. 1.2 months, P < 0.001). Notably, even in the wild-type EGFR subgroup, pTyr1068-positive patients showed significantly prolonged PFS (4.2 months vs. 1.2 months, P < 0.001) .
How do quantitative differences in Y1068 phosphorylation affect downstream signaling outcomes?
Quantitative analysis reveals that EGFR phosphorylation and subsequent signaling follow a dose-response pattern to ligand stimulation. The relationship between EGF concentration and Y1068 phosphorylation is not simply linear but involves complex regulatory mechanisms. Mathematical modeling suggests that cooperativity between multiple phosphorylation sites, including Y1068, contributes to establishing thresholds for cellular responses. This cooperativity is particularly evident in the relationship between phosphorylation and ubiquitination, where Y1068 (along with Y1086) serves as a binding site for Grb2:Cbl complexes that mediate receptor ubiquitination and downregulation .
What are the optimal conditions for detecting phospho-EGFR (Y1068) by Western blotting?
For optimal detection by Western blotting:
| Parameter | Recommended Condition |
|---|---|
| Membrane | PVDF |
| Antibody concentration | 1 μg/mL |
| Secondary antibody | HRP-conjugated Anti-Mouse IgG |
| Running conditions | Reducing conditions |
| Buffer system | Immunoblot Buffer Group 1 |
| Expected band size | Approximately 190 kDa |
| Positive control | A431 cells treated with 100 ng/mL EGF for 5 minutes |
| Negative control | Untreated A431 cells |
It is critical to include phosphatase inhibitors in lysis buffers and to maintain samples at cold temperatures during processing to preserve phosphorylation status .
How can I optimize intracellular flow cytometry for phospho-EGFR (Y1068) detection?
Successful intracellular flow cytometry for phospho-EGFR (Y1068) requires:
-
Proper fixation: Use paraformaldehyde (typically 4%) to preserve cellular architecture and phosphorylation status.
-
Effective permeabilization: Saponin is commonly used to allow antibody access to intracellular antigens.
-
Blocking: Include appropriate blocking reagents to reduce non-specific binding.
-
Controls: Always include an isotype control (e.g., Mouse IgG2A) and both stimulated and unstimulated samples.
-
Secondary detection: For unconjugated primary antibodies, use fluorochrome-conjugated secondary antibodies like Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2.
This approach has been successfully demonstrated in A431 cells treated with EGF, showing clear shifts in phospho-EGFR signal compared to untreated controls .
What are the advantages of using LANCE Ultra assays for phospho-EGFR (Y1068) detection compared to traditional methods?
LANCE Ultra assays offer several methodological advantages for phospho-EGFR (Y1068) detection:
-
Homogeneous format: No wash steps required, simplifying workflow and reducing variability.
-
Compatibility: Works with both adherent and suspension cells.
-
Low sample requirement: Only 15 μL of sample needed.
-
Time-resolved detection: Utilizes TR-FRET (time-resolved fluorescence resonance energy transfer) technology, reducing background interference.
-
Quantitative results: Provides ratiometric data (665/615 nm X 10,000) for more reliable quantification.
This technology combines a donor fluorophore (LANCE Europium chelate) on one antibody with an acceptor fluorophore (ULight dye) on another, enabling energy transfer when the antibodies are in close proximity (~10 nm) following excitation at 320 or 340 nm .
How can phospho-EGFR (Y1068) expression be used as a biomarker in cancer therapy selection?
Research has demonstrated that phospho-EGFR (Y1068) expression may serve as a valuable predictive biomarker for EGFR-TKI therapy response, independent of EGFR mutation status. In non-small cell lung cancer, patients with pTyr1068 expression showed significantly better outcomes with EGFR-TKI treatment. Particularly notable was the identification of a subgroup of patients with wild-type EGFR but positive pTyr1068 expression who responded well to EGFR-TKIs, with a median progression-free survival of 15.6 months (95% CI: 7.28-23.9). This suggests that immunohistochemical assessment of pTyr1068 could help identify additional patients who might benefit from EGFR-targeted therapies beyond those selected by mutation testing alone .
What is the relationship between phospho-EGFR (Y1068) and other phosphorylation sites in predicting clinical outcomes?
The relationship between different EGFR phosphorylation sites provides complex regulatory information. While pTyr1068 expression correlates with improved outcomes on EGFR-TKI therapy, pTyr1173 shows an inverse relationship, with patients expressing pTyr1173 having shorter progression-free survival (4.8 months vs. 7.7 months, P = 0.016). This differential impact of various phosphorylation sites highlights the complexity of EGFR signaling networks and suggests that comprehensive phosphorylation profiling might provide more nuanced predictive information than single-site analysis. The molecular basis for these differences may lie in the recruitment of distinct adaptor proteins and activation of different downstream signaling pathways .
How does phospho-EGFR (Y1068) status inform resistance mechanisms to EGFR-targeted therapies?
Understanding phospho-EGFR (Y1068) status in the context of treatment resistance provides important mechanistic insights. Patients who initially respond to EGFR-TKIs based on pTyr1068 expression may develop resistance through various mechanisms, including:
-
Bypass pathway activation: Alternative signaling pathways may become activated, reducing dependence on EGFR.
-
Phosphatase upregulation: Increased expression or activity of phosphatases that dephosphorylate Y1068.
-
Altered receptor trafficking: Changes in receptor internalization and degradation pathways.
-
Secondary mutations: Acquisition of mutations that prevent inhibitor binding while maintaining Y1068 phosphorylation.
Monitoring changes in pTyr1068 status during treatment could potentially help identify emerging resistance mechanisms and inform subsequent treatment decisions .
What are common causes of false negative results when detecting phospho-EGFR (Y1068)?
False negative results when detecting phospho-EGFR (Y1068) may stem from several methodological issues:
-
Rapid dephosphorylation: Phosphorylation is highly labile and can be lost during sample preparation. Always include phosphatase inhibitors in lysis buffers.
-
Insufficient stimulation: For positive controls, ensure adequate stimulation (e.g., 100 ng/mL EGF for 5 minutes for A431 cells).
-
Antibody concentration: Using too dilute antibody preparation (optimal concentration is typically 1 μg/mL for Western blot).
-
Ineffective permeabilization: For flow cytometry, inadequate permeabilization with saponin can prevent antibody access to intracellular antigens.
-
Sample degradation: Repeated freeze-thaw cycles or prolonged storage at inappropriate temperatures can degrade phosphorylated proteins .
How can I differentiate between EGFR kinase-dependent and kinase-independent phosphorylation at Y1068?
To distinguish between kinase-dependent and kinase-independent phosphorylation mechanisms:
-
Use specific EGFR kinase inhibitors (e.g., C56 at 1 μM) as pretreatment before stimulation. If Y1068 phosphorylation is abrogated by the inhibitor, it suggests kinase-dependent mechanisms.
-
Compare phosphorylation patterns across multiple sites - different mechanisms may preferentially affect certain sites.
-
Investigate time-course dynamics, as kinase-dependent and independent mechanisms often show different temporal profiles.
-
Examine phosphorylation in the presence of Src inhibitors, as Src-mediated phosphorylation of EGFR can occur independently of EGFR's intrinsic kinase activity in some contexts.
Research has shown that ozone-induced EGFR (Y1068) phosphorylation in human bronchial epithelial cells requires EGFR kinase activity, as it was abrogated by kinase inhibition .
What experimental considerations are crucial when studying phospho-EGFR (Y1068) in complex biological samples?
When working with complex biological samples such as tissue lysates or clinical specimens:
-
Sample preservation: Rapid freezing and proper storage are essential to maintain phosphorylation status.
-
Normalization strategies: Use total EGFR levels for normalization rather than housekeeping proteins alone.
-
Heterogeneity considerations: Cell-type specific expression patterns may be masked in whole-tissue lysates.
-
Validation across methods: Confirm key findings using orthogonal techniques (e.g., both Western blot and immunohistochemistry).
-
Contextual interpretation: Consider the broader signaling environment, including the status of phosphatases, RTK crosstalk, and downstream effectors.
-
Appropriate controls: Include both positive controls (e.g., EGF-stimulated cell lines) and negative controls (untreated samples or those treated with kinase inhibitors).
These considerations are particularly important in clinical research settings where sample quality and processing methods can significantly impact results and their interpretation .
